Biotech Hunter
Biotech Hunter
Home
Companies
Trials
People
Search
Clinical Trials for BioTherapeutics Inc
Explore 26 clinical trials worldwide
Search
Showing 1-26 of 26 trials
Active filters:
Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruiting
Sponsor: BioTherapeutics Inc
Clinical Trials (26)
NCT07192432
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
PHASE1/PHASE2
Recruiting
27 participants
Started: Nov 30, 2025 · Completed: Oct 31, 2033
1 condition
1 sponsor
2 locations
NCT06885424
A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products
N/A
Enrolling by invitation
400 participants
Started: Aug 31, 2025 · Completed: Mar 31, 2040
15 conditions
1 sponsor
2 locations
NCT06533579
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
PHASE1/PHASE2
Recruiting
32 participants
Started: May 30, 2025 · Completed: Sep 30, 2031
13 conditions
1 sponsor
8 locations
NCT06682793
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
PHASE1/PHASE2
Recruiting
240 participants
Started: May 22, 2025 · Completed: Mar 31, 2030
17 conditions
1 sponsor
10 locations
NCT06737354
Safety and Efficacy Study of IVB103 Injection in Subjects With Neovascular (Wet) Agerelated Macular Degeneration (nAMD).
PHASE1
Enrolling by invitation
18 participants
Started: Apr 22, 2025 · Completed: Dec 31, 2031
1 condition
2 sponsors
1 location
NCT06667960
Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer
PHASE1/PHASE2
Recruiting
155 participants
Started: Oct 23, 2024 · Completed: Aug 1, 2028
1 condition
1 sponsor
8 locations
NCT06539338
Safety of INT2104 in Participants Aged 18 Years and Older Who Have B-cell Cancer That Came Back After Prior Treatment
PHASE1
Recruiting
34 participants
Started: Oct 7, 2024 · Completed: Mar 31, 2031
2 conditions
1 sponsor
2 locations
NCT06524063
Targeted Survivin DC Cell Injection for the Treatment of GBM
PHASE1
Not yet recruiting
9 participants
Started: Aug 1, 2024 · Completed: Oct 1, 2027
1 condition
1 sponsor
0 locations
NCT06373731
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
PHASE3
Recruiting
360 participants
Started: May 30, 2024 · Completed: Aug 31, 2027
1 condition
1 sponsor
63 locations
NCT06051695
A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
PHASE1/PHASE2
Recruiting
230 participants
Started: Apr 3, 2024 · Completed: Jun 30, 2029
20 conditions
2 sponsors
11 locations
NCT06369298
Study of JK07 in Patients With Chronic Heart Failure
PHASE2
Recruiting
282 participants
Started: Mar 28, 2024 · Completed: Jun 30, 2026
2 conditions
1 sponsor
62 locations
NCT06224413
A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel
N/A
Recruiting
120 participants
Started: Mar 27, 2024 · Completed: Dec 30, 2047
1 condition
2 sponsors
3 locations
NCT06289452
Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked Retinoschisis
EARLY_PHASE1
Active, not recruiting
18 participants
Started: Mar 8, 2024 · Completed: Dec 31, 2029
4 conditions
2 sponsors
1 location
NCT06328673
A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
PHASE1
Recruiting
160 participants
Started: Mar 1, 2024 · Completed: Mar 1, 2026
1 condition
1 sponsor
2 locations
NCT06271512
A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel
N/A
Recruiting
150 participants
Started: Jan 23, 2024 · Completed: Dec 31, 2043
1 condition
2 sponsors
6 locations
NCT05736731
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
PHASE1/PHASE2
Active, not recruiting
160 participants
Started: Apr 28, 2023 · Completed: Dec 31, 2026
16 conditions
2 sponsors
8 locations
NCT05620134
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
PHASE1/PHASE2
Active, not recruiting
263 participants
Started: Oct 17, 2022 · Completed: Feb 20, 2026
22 conditions
1 sponsor
11 locations
NCT05353647
A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (GRASP, BMT CTN 2001)
PHASE2
Active, not recruiting
25 participants
Started: Jul 12, 2022 · Completed: Jul 31, 2027
1 condition
5 sponsors
9 locations
NCT05162768
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)
PHASE3
Active, not recruiting
102 participants
Started: Apr 29, 2022 · Completed: Oct 31, 2024
8 conditions
1 sponsor
32 locations
NCT04981119
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
N/A
Recruiting
200 participants
Started: Oct 29, 2021 · Completed: Dec 31, 2026
17 conditions
2 sponsors
15 locations
NCT04722354
Abscisic Acid Effects on Glucose Homeostasis and Insulin Sensitivity
PHASE2
Active, not recruiting
48 participants
Started: Mar 8, 2021 · Completed: Dec 31, 2025
1 condition
2 sponsors
1 location
NCT04628585
Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene Therapy
N/A
Enrolling by invitation
85 participants
Started: Oct 21, 2020 · Completed: Jan 31, 2038
1 condition
1 sponsor
16 locations
NCT04293185
A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease
PHASE3
Active, not recruiting
35 participants
Started: Feb 14, 2020 · Completed: Nov 30, 2027
1 condition
1 sponsor
9 locations
NCT03131934
Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant
EARLY_PHASE1
Active, not recruiting
18 participants
Started: May 31, 2019 · Completed: May 15, 2025
2 conditions
2 sponsors
2 locations
NCT02698579
Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product
N/A
Active, not recruiting
64 participants
Started: Jan 22, 2016 · Completed: Aug 31, 2038
3 conditions
1 sponsor
13 locations
NCT02633943
Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy
N/A
Active, not recruiting
66 participants
Started: Jan 31, 2014 · Completed: Nov 30, 2035
1 condition
1 sponsor
15 locations